曼恩凱德生物醫療 MNKD 深 滬
已收盤 02-06 16:00:00 美东时间
5.78
+0.270
+4.90%
華盛通- 最 高5.86
- 今 開5.59
- 成交量 301.26万股
- 最 低 5.525
- 昨 收 5.51
- 總市值 17.75亿
- 52周最高 6.51
- 市盈率 靜 59.47
- 換手率 0.98%
- 52周最低 3.3812
- 委 比 -33.00%
- 總股本 3.07亿
- 歷史最高 57.40
- 量 比 0.70
- 振 幅 6.08%
- 歷史最低 0.666
- 每 手 1
- 風險率 0.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
BRIEF-MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
BRIEF-MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy Jan 26 (Reuters) - MannKind Corp MNKD.O : MANNKIND ANNOUNCES FDA APPROVAL OF UPDATED AFREZZA® LABEL PROVIDING STARTING
01-26 19:06
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
The U.S. Food and Drug Administration (FDA) has approved an update to the Prescribing Information for Afrezza® (insulin human) Inhalation Powder, revising recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. The update is based on clinical trials showing improved mealtime glycemic control and includes a revised dosing table to support a safer transition. The new guidance aims to provid...
01-26 11:05
MannKind Provides Business Updates and 2026 Growth Drivers
MannKind Corporation provided updates on business progress and growth drivers for 2026, including FDA decisions on Afrezza label updates and pediatric use, FUROSCIX ReadyFlow Autoinjector review, pipeline developments for nintedanib and bumetanide DPIs, and collaborations with United Therapeutics.
01-08 13:05
MannKind Shares FUROSCIX® Business Updates
FDA approves FUROSCIX for pediatric patients weighing 43kg or above, expanding its use beyond adults with chronic heart failure and kidney disease. Additionally, five new patents for the FUROSCIX ReadyFlow Autoinjector provide extended intellectual property protection through 2040, reinforcing MannKind's position. The autoinjector, currently under FDA review, aims to deliver diuretic doses in seconds, potentially reducing hospital visits and impr...
2025-12-23 13:05
MannKind's Furoscix Autoinjector under FDA review for expanded label
MannKind Corporation (MNKD) said that the U.S. FDA has accepted its supplemental new drug application for the Furoscix ReadyFlow Autoinjector. This device is designed to help patients administer thei...
2025-12-01 22:21
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Truist Securities Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $9
Truist Securities analyst Gregory Renza initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $9.
2025-11-25 01:59
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $8
Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $10 to $8.
2025-11-11 22:33
